Because αvβ3-dependent activation of the MAPK pathway was previously found to drive CCN1-directed cell survival and chemoresistance [30], we explored whether specific modulation of the CCN1-integrin(s) binding differentially altered ERK1/ERK2 activity in breast cancer cells. The gene discussed is MAPK1; the disease is breast cancer.